Format

Send to

Choose Destination
Oral Oncol. 2010 Jan;46(1):4-8. doi: 10.1016/j.oraloncology.2009.09.004. Epub 2009 Nov 4.

Development of a gene transfer-based treatment for radiation-induced salivary hypofunction.

Author information

1
National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA. bbaum@dir.nidcr.nih.gov

Abstract

A significant long-term side effect of radiation therapy for head and neck cancers is xerostomia, a dry mouth, due to salivary gland damage. Despite continuing efforts to eliminate this problem, many patients continue to suffer. This brief review describes our efforts to develop a gene transfer approach, employing the aquaporin-1 cDNA, to treat patients with existing radiation-induced salivary hypofunction. A Phase I/II clinical trial, using a recombinant adenoviral vector to mediate gene transfer, is currently underway.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00372320.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center